References
- 1..Xiong HJ, Yu HQ, Zhang J, Fang L, Wu D, Lin XT, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Mil Med Res. 2023;10(1):68.
- 2..Shubhra QTH. RARRES2’s impact on lipid metabolism in triple-negative breast cancer: a pathway to brain metastasis. Mil Med Res. 2023;10(1):42.
- 3..Zaman R, Cai X, Shubhra QTH. Hyperthermia-embolization-immunotherapy: a potent trio in advancing cancer treatment. Trends Mol Med. 2023;29(12):976–8.
- 4..Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.
- 5..Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.
- 6..Guo K, Xiao N, Liu Y, Wang Z, Tóth J, Gyenis J, et al. Engineering polymer nanoparticles using cell membrane coating technology and their application in cancer treatments: opportunities and challenges. Nano Mater Sci. 2022;4(4):295–321.

